The beneficial measures concerning 200 million investors have come.
According to the news released today on the official website of China Securities Depository and Clearing Co., Ltd. (hereinafter referred to as “CSDCC”), CSDCC will generally reduce the stock transaction transfer fee by 50% from April 29, 2022.
The transfer fee for stock trading is charged from 0.02 ‰ of the transaction amount for A-Shares in Shanghai and Shenzhen market and 0.025 ‰ of the transaction amount for A-Shares in Beijing market and shares of listed companies, which is uniformly reduced to 0.01 ‰ of the transaction amount.
According to the official website of China Clearing, China Clearing adjusted the charging standard of transfer fee for A-share transactions in order to deeply implement the spirit of the special meeting of the financial commission of the State Council, promote the stable and healthy operation of the capital market, further stimulate market vitality and increase support for the real economy by reducing investor costs.
In mid March, in order to reduce the market capital cost and cooperate with the ongoing DVP reform, CSDCC announced that from April 2022, the payment proportion of the minimum settlement provision for stock business would be reduced from 18% to 16%, and some registration and settlement fees such as the registration fee of stock securities of two networks and delisting companies, the non trading transfer fee of B shares and bonds, and the commission fee for dividend distribution of closed-end funds would be exempted from being registered in Tianjin The issuer’s registration and settlement expenses in 2022 in Inner Mongolia Autonomous Region, Jilin Province, Shanghai, Shandong Province, Henan Province, Shaanxi Province, Shenzhen and other regionsP align = “center” shares targeted by foreign investors at the same time, p align = “center” has one thing in common
Buffett has a famous saying: greed when others are afraid, fear when others are greedy. However, when the market really fluctuates sharply, not many investors dare to buy against the trend.
With the release of the first quarterly report of the fund and the disclosure of the first quarterly report of listed companies, the latest positions of mainstream institutional investors such as public offering and foreign capital have surfaced. Since the beginning of this year, despite the continuous adjustment of the A-share market and the significant retreat of many early popular tracks, many investment targets have been “matched” by public funds and overseas asset management giants at the same time. From a fundamental point of view, the performance of these stocks increased significantly in the first quarter of this year.
In addition, the reporter found that some companies recently disclosed the latest number of shareholders in mid April. Compared with the end of March, the chip concentration of some companies increased significantly. These companies are mainly distributed in pharmaceutical and biological, basic chemical, mechanical equipment and other industries.
domestic and foreign capital group performance substantial increase in shares
Choice data show that according to the disclosed data, some stocks with excellent performance in the first quarter are “favored” by public offering and foreign investment at the same time.
Taking Longyan Zhuoyue New Energy Co.Ltd(688196) as an example, by the end of the first quarter of this year, there were two QFII and seven public funds among the top ten circulating shareholders of the company. Among them, UBS and Merrill Lynch increased their holdings by 750000 shares and 159000 shares respectively, ranking the first and sixth largest shareholders of tradable shares. The seven public funds were new in the first quarter of this year.
According to the first quarterly report of the company, Longyan Zhuoyue New Energy Co.Ltd(688196) 2022 achieved an operating revenue of 977 million yuan in the first quarter, a year-on-year increase of 143%; The net profit attributable to the parent company was 100 million yuan, a year-on-year increase of 75% According to the analysis of Guotai Junan Securities Co.Ltd(601211) Research Report, the company’s operating revenue and attributable net profit increased steadily, mainly due to the strong demand for biodiesel and the rise in export volume and price. The demand for biodiesel in Europe is strong, and China’s waste classification is actively promoted. As China’s largest biomass diesel export enterprise, the company will fully benefit.
Zhejiang Jiaao Enprotech Stock Co.Ltd(603822) was also increased by public funds and QFII in the first quarter of this year. According to the data, the Hong Kong Monetary Authority bought 540000 shares of Zhejiang Jiaao Enprotech Stock Co.Ltd(603822) , ranking the tenth largest shareholder of circulating shares of the company in the first quarter; Dongfanghong innovation trend mix, Yuanxin Yongfeng Youjia life stock and Yuanxin Yongfeng Xingnuo holding mix for one year also ranked among the top ten circulating shareholders of the stock in the first quarter.
Zhejiang Jiaao Enprotech Stock Co.Ltd(603822) in the first quarter performance announcement released on April 22, the company achieved an operating revenue of about 517 million yuan in the first quarter of this year, with a year-on-year increase of 62.09%; The net profit attributable to the shareholders of the listed company was about 28.1 million yuan, a year-on-year increase of 33.82%.
According to the latest quarterly report of the fund, BlackRock China new vision hybrid, the first pure foreign-funded public offering fund, made a significant position adjustment in the first quarter of this year, and Sg Micro Corp(300661) replaced Luxshare Precision Industry Co.Ltd(002475) to become the largest heavy position stock of the fund.
It is worth noting that Sg Micro Corp(300661) has also been favored by many public funds. According to statistics, as of the end of the first quarter, a total of 42 funds took Sg Micro Corp(300661) as the largest heavy position stock; At the end of the fourth quarter of last year, only six funds took the stock as the largest heavy position stock.
According to the Sg Micro Corp(300661) announcement, the company achieved an operating revenue of 775 million yuan in the first quarter of 2022, with a year-on-year increase of 96.81%; The net profit attributable to shareholders of listed companies was 260 million yuan, a year-on-year increase of 244.98%.
investment mainline returns to fundamentals
At the current time point, many domestic and foreign-funded institutions believe that at present, both China and abroad are facing the pattern of shortage of high-quality assets for a long time. As the most representative asset of China’s economy, A-Shares have enough attraction to global investors, and they are optimistic about the structural opportunities of the equity market in the future. With the gradual release of risk sentiment and the disclosure of the first quarterly reports of listed companies, the main line of investment in the future will return to the fundamentals of the company.
“In the short and medium term, although growth stocks will face various pressures and challenges, with the digestion of valuation, many stock valuations have fallen back to a reasonable or even low range. The first quarterly report will provide a good appraisal opportunity for us to better find out and make up for deficiencies.” Chen Qi, head of Huafu fund research department and fund manager, said.
Zhou Ping, director of China quantitative investment of lubemaker, said that due to the extreme interpretation of growth style in the past few years, the valuation of value stocks has been seriously compressed, and their profitability and growth prospects have been restored. Therefore, he believes that industries that underestimate the value and benefit from the “steady growth” policy, such as construction, real estate and finance, will continue to lead the market.
“In terms of growth stocks, the fundamental outlook is still very high. The recent huge pullback is, on the one hand, the repair of the valuation of the past two years, and on the other hand, the reflection of capital chasing up and down. In terms of valuation, the valuation of growth stocks has been attractive, but the key to the recovery of growth stocks lies in the change of market sentiment.” Zhou Ping said.
Jiang Zhenghao, equity investment manager of baring China, said that he would take a positive view of the medium and long-term prospects of Chinese enterprises and continue to be optimistic about the investment themes with structural growth opportunities in the 14th five year plan – consumption upgrading, scientific and technological innovation, green energy development, etc.
just half a month, the chips are concentrated greatly,
who is raising money
According to the statistics of the reporter of Shanghai Securities News, after excluding the new shares listed since this year, the number of shareholders of 25 shares decreased by more than 10% from the end of March to April 20.
Among which, Naipu Mining Machinery Co.Ltd(300818) thenumber of shareholders decreased by more than 15%.
Naipu Mining Machinery Co.Ltd(300818) has the largest increase in chip concentration. The number of shareholders on March 31 was 15319, and by April 20 it had dropped to 11612, a full decrease of 3707, a decrease of 24%. The company’s share price fell 27% in this range.
Naipu Mining Machinery Co.Ltd(300818) is a professional manufacturer of heavy mine beneficiation equipment and wear-resistant spare parts of new materials. In the first quarter of this year, the operating revenue was 224 million yuan, an increase of 155% year-on-year; The net profit attributable to the shareholders of the listed company was 59.67 million yuan, a year-on-year increase of 405%; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses increased by 213% year-on-year. The company actively explored the market outside China, and the contract amount reached 170 million yuan, an increase of 39% over the same period in 2021. The company has sufficient orders and good year-on-year growth in sales revenue.
It is worth noting that since this year, the company has obtained intensive research from many institutions, including public funds, private placement and securities companies, and held 7 video conference research. Among them, there are also well-known fund managers such as bocom Schroeder Yang Jinjin and Nanfang fund Mao Wei.
In the institutional research, the company said that the overall gross profit margin of foreign customers is about 45%, and the comprehensive average gross profit margin of Chinese customers is 32-35%. The company’s future focus is to develop international customers, and the international business income should reach 80% of the company’s overall revenue.
Zhejiang Zhongxin Fluoride Materials Co.Ltd(002915) the number of shareholders in the latest phase dropped sharply by 21%. The number of shareholders was 24017 on March 31 and 18935 on April 20. In the early stage, affected by the rumor of “cooperative development of oral drugs for covid-19 virus”, the company’s share price rose continuously, while it has fallen by 37% since the end of March. Strangely, in the process of sharp decline in share price, the number of shareholders continued to decrease.
Zhejiang Zhongxin Fluoride Materials Co.Ltd(002915) since its establishment, it has been focusing on the business of fluorine-containing intermediates in medicine and pesticides. On the one hand, it has expanded new material products from a single bpef to DFBP, tfmb and other products; On the other hand, it extends the industrial chain upward. At present, the company has become a characteristic enterprise with the layout of the whole industrial chain of fluorine fine chemical industry. The company benefited from the sharp rise in the price of sulfuric acid and hydrofluoric acid, as well as the initial formation of the vertical integrated industrial chain layout of the company’s medicine, pesticide and new materials. The performance increased steadily in the first quarter of 2021 and 2022.
multiple funds involved China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999)
From the perspective of industry distribution, the 25 stocks with a decrease of more than 10% in the number of shareholders are mainly distributed in pharmaceutical and biological, basic chemical, mechanical equipment and other industries, with 5, 4 and 3 companies respectively.
The reporter found that the traditional Chinese medicine sector has been significantly favored by funds. Not only did the number of shareholders of three traditional Chinese medicine stocks drop significantly, but also there was a leader in traditional Chinese Medicine China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) .
China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) from March 31, the number of shareholders showed a continuous downward trend, from 41921 on March 31 to 37489 on April 8, and then to 35222 on April 20, with a cumulative decline of about 20% in 20 days. Obviously, the continuous mobilization of funds is one of the important factors that promote the performance of the company’s share price to be significantly stronger than the market.
Sanjiu Pharmaceutical Co., Ltd. is a large state-owned listed pharmaceutical company, with its main core business positioned at OTC and traditional Chinese medicine prescription drugs. OTC core products occupy a high market share in the fields of cold, gastrointestinal, skin, pediatrics, cough and orthopedic drugs; Prescription drug products rank at the forefront of the Chinese market in the fields of traditional Chinese medicine formula granules, cardio cerebrovascular, anti-tumor and anti infection. The first quarterly report disclosed by the company recently showed that the revenue was 4.194 billion yuan, a year-on-year increase of 2.81%; The net profit attributable to the parent company was 839 million yuan, a year-on-year increase of 30.45%.
Excellent performance has also attracted heavy buying by well-known fund managers. According to the first quarterly report of the fund, Zhao Bei, a medical star fund manager, bought Sanjiu pharmaceutical with three funds at the same time. In the first quarter, ICBC Credit Suisse Frontier Medical under its management directly increased its holdings of China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) 15 million shares, which is the seventh largest heavy stock of the fund, with a market value of 680 million yuan; ICBC Credit Suisse pension industry fund newly entered 3.9886 million shares, with a market value of 180 million yuan, ranking the ninth largest circulating shareholder of the company; ICBC Credit Suisse growth select fund was established in March last year and held 1.4245 million shares of Sanjiu pharmaceutical in the first quarter, becoming the seventh largest heavy stock of the fund.
In addition, Taiping Life Insurance, e fund for healthcare industry, huitianfu innovative medicine theme fund and other institutions have all recently appeared on the list of the top ten shareholders of the company.
